FindTrial
Sign In

AZD1390

DRUG7 trials

Sponsors

Global Coalition For Adaptive Research Inc., AstraZeneca, Global Coalition for Adaptive Research, University of Leeds, Nader Sanai

Conditions

Advanced Solid MalignanciesBrain Neoplasms, MalignantGlioblastomaGlioblastoma MultiformeGliomaGlioma, MalignantLeptomeningeal Disease (LMD)Metastatic Cancer

Early Phase 1

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Active, not recruitingNCT05182905
Nader SanaiGlioblastoma, Glioblastoma Multiforme, Glioma +1
Start: 2022-05-27End: 2026-12-10Target: 97Updated: 2026-03-09

Phase 1

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Active, not recruitingNCT03423628
AstraZenecaBrain Neoplasms, Malignant, Leptomeningeal Disease (LMD), Primary Glioblastoma Multiforme +1
Start: 2018-04-02End: 2026-09-03Updated: 2026-07-17
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
RecruitingNCT04550104
University of LeedsNon Small Cell Lung Cancer
Start: 2021-03-17End: 2028-03-31Target: 200Updated: 2025-12-19
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Active, not recruitingNCT05678010
Memorial Sloan Kettering Cancer CenterMetastatic Cancer, Metastatic Solid Tumor, Metastatic Tumor +3
Start: 2023-05-17End: 2028-05-17Target: 54Updated: 2026-05-18
Human ADME Study of [14C]-AZD1390
Not yet recruitingNCT07643870
AstraZenecaAdvanced Solid Malignancies
Start: 2026-06-30End: 2028-04-12Target: 8Updated: 2026-06-12

Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RecruitingNCT03970447
Global Coalition for Adaptive ResearchGlioblastoma
Start: 2019-07-30End: 2030-06-01Target: 2250Updated: 2026-07-13
GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)
RecruitingCTIS2024-511452-40-00
Global Coalition For Adaptive Research Inc.Oncology - Glioblastoma (GBM)
Start: 2025-09-12Target: 120Updated: 2025-09-12

Related Papers

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
2026-04-14
TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Neuro-Oncology2025-11-01
Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
Journal of Clinical Oncology2025-05-281 citations
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology2024-11-012 citations
CTIM-16. SAFETY AND PRELIMINARY EFFICACY OF AZD1390 + RADIATION THERAPY FOR GLIOBLASTOMA
Neuro-Oncology2024-11-011 citations
CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology2024-11-01
CTNI-55. A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN NEWLY DIAGNOSED, MGMT-UNMETHYLATED AND RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology2024-11-01
OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
Neuro-Oncology2024-10-012 citations
JS02.5.A A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology2024-10-011 citations
KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology2024-10-01
P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology2024-10-01
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.
Journal of Clinical Oncology2024-06-011 citations
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Communications Medicine2024-05-216 citations
Abstract CT044: A phase 0/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patients
Cancer Research2024-04-05
Abstract IA006: Multifaceted effects of DNA damage response inhibitors on radiation responses of glioblastoma and the normal brain
Cancer Research2024-01-09
Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors
European Journal of Cancer Care2024-01-011 citations
CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
Neuro-Oncology2023-11-0117 citations
CTNI-25. A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology2023-11-011 citations
P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology2023-09-01
Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.
Journal of Clinical Oncology2023-06-013 citations

13 more papers not shown